Coronavirus Disease 2019 in the Early Postoperative Period of Liver Transplantation: Is the Outcome Really So Positive?

Daniel Reis Waisberg, Edson Abdala, Lucas Souto Nacif, Liliana Ducatti, Luciana Bertocco Haddad, Rodrigo Bronze Martino, Rafael Soares Pinheiro, Rubens Macedo Arantes, Flavio Henrique Galvao, Larissa Nunes Gouveia, Debora Raquel Terrabuio, George Felipe Darce, Vinicius Rocha‐Santos, Wellington Andraus, Luiz Augusto Carneiro‐D’Albuquerque – 9 November 2020

Multicenter, Double‐Blind, Randomized Trial of Emricasan in Hepatitis C–Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis

Ethan M. Weinberg, Michael P. Curry, Catherine T. Frenette, Fredric G. Regenstein, Eugene R. Schiff, Zachary D. Goodman, James M. Robinson, Jean L. Chan, Joanne C. Imperial, K. Rajender Reddy – 8 November 2020 – Despite achieving sustained virologic response (SVR) to hepatitis C virus (HCV) therapy, there remains a post liver transplantation population with advanced fibrosis/cirrhosis. Emricasan is an orally active, pan‐caspase inhibitor that suppresses apoptosis and inflammation, potentially decreasing hepatic inflammation and fibrosis.

Impacts of Early Kasai Portoenterostomy on Short‐Term and Long‐Term Outcomes of Biliary Atresia

Ryuji Okubo, Masaki Nio, Hideyuki Sasaki, the Japanese Biliary Atresia Society – 8 November 2020 – There are discrepancies regarding the clinical impact of age at Kasai portoenterostomy (KP) on surgical outcomes. Hence, we re‐assessed the clinical significance of age at KP. We analyzed 224 patients with type III (atresia of bile duct at the porta hepatis) biliary atresia at Tohoku University Hospital. We classified patients into two groups: KP at ≤60 days of age (group TE) and >60 days of age (group TL).

A Population‐Based Intervention to Improve Care Cascades of Patients With Hepatitis C Virus Infection

John Scott, Meaghan Fagalde, Atar Baer, Sara Glick, Elizabeth Barash, Hilary Armstrong, Kris V. Kowdley, Matthew R. Golden, Alexander J. Millman, Noele P. Nelson, Lauren Canary, Matthew Messerschmidt, Pallavi Patel, Michael Ninburg, Jeff Duchin – 7 November 2020 – Hepatitis C virus (HCV) infection is common in the United States and leads to significant morbidity, mortality, and economic costs. Simplified screening recommendations and highly effective direct‐acting antivirals for HCV present an opportunity to eliminate HCV.

Endothelial p300 Promotes Portal Hypertension and Hepatic Fibrosis Through C‐C Motif Chemokine Ligand 2–Mediated Angiocrine Signaling

Jinhang Gao, Bo Wei, Mengfei Liu, Petra Hirsova, Tejasav S. Sehrawat, Sheng Cao, Xiao Hu, Fei Xue, Usman Yaqoob, Ningling Kang, Huarui Cui, William C.K. Pomerantz, Enis Kostallari, Vijay H. Shah – 7 November 2020

Degree of Portal and Systemic Hemodynamic Alterations Predict Recurrent AKI and Chronic Kidney Disease in Patients With Cirrhosis

Rakhi Maiwall, Samba Siva Rao Pasupuleti, Priyanka Jain, Shiv Kumar Sarin – 6 November 2020 – The relevance of hemodynamic derangements on the incidence of recurrent acute kidney injury (AKI) and chronic kidney disease (CKD) in patients with cirrhosis is largely unknown. Consecutive patients with cirrhosis with a complete record of baseline hemodynamics were followed for identifying risk factors for the development of recurrent AKI and CKD by using negative binomial regression and competing risk analysis, respectively.

Hepatology Highlights

Nicholas W. Russo, Robert S. Brown, Gopanandan Parthasarathy, Robert E. Schwartz, Adam Buckholz, Arun B. Jesudian, Enis Kostallari, Cesar Taborda, Joel Wedd, Tejasav S. Sehrawat, Navid Hejazifar, Lauren M. Yang, Daryl T.Y. Lau, Jessica Maiers, Nidhi Jalan‐Sakrikar – 6 November 2020

Subscribe to